Multicentral Preventive Antibiotics With Cystectomy Within Enhanced Recovery After Surgery

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE3

Total Enrollment

98 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-02-02

Study Completion Date

2023-11-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The current usage of antibiotic prophylaxis (AP) in radical cystectomy (RC) is aimed to reducing the incidence of surgical site infections and incidence of unnecessary prescribing of antibiotics. There are a huge number of different AP protocols according to Urological Associations. However, there is no convincing evidence to support variations and duration of AP which requires a randomized clinical trial on AP when performing variants of RC with uroderivation.

Research hypothesis: The use of prolonged antibiotic prophylaxis (5 days), depending on the glomerular filtration rate, does not affect the incidence of postoperative complications.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Antibiotic Prophylaxis in Transurethral Prostate Resection (TURP) and Transurethral Bladder Tumour Resection (TURB)

NCT04212403

Urosepsis Bladder Cancer Prostate Hyperplasia +4 more

COMPLETED NA

Antibiotic Prophylaxis for Urinary Catheter Removal After Radical Prostatectomy

NCT02247960

Prostate Cancer Urinary Tract Infection Clostridium Difficile

TERMINATED NA

Comprehensive Optimization At-time of Radical Cystectomy Intervention

NCT05714826

Bladder Cancer Radical Cystectomy

RECRUITING NA

Discharge Medication Use Post-Operatively in GU Cancer Patients

NCT06795087

Genitourinary Cancer

RECRUITING

Peri-operative Tamsulosin and Impact on Voiding Trial After Same-day Urogynecology Surgery

NCT06843538

Postoperative Urinary Retention (POUR)

RECRUITING PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bladder Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Amoxicillin/ Cefuroksim

standard antibiotic prophylaxis 24 hours

Group Type ACTIVE_COMPARATOR

Amoxicillin+clavulanic acid 1200 mg or Cefuroksim 1500mg

Intervention Type DRUG

Group A: antibiotic prophylaxis within 24 hours from the moment of skin incision according to local clinical practice;

Meropenem

preventive antibiotic therapy within 5 days from the date of the skin incision

Group Type EXPERIMENTAL

Meropenem 1000 mg

Intervention Type DRUG

Group B: prolonged antibiotic prophylaxis \>72 hours (5 days) from the moment of the skin incision in accordance with the selected clinic drug + correction of the appointment based on clinical events after 5 days.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Meropenem 1000 mg

Group B: prolonged antibiotic prophylaxis \>72 hours (5 days) from the moment of the skin incision in accordance with the selected clinic drug + correction of the appointment based on clinical events after 5 days.

Intervention Type DRUG

Amoxicillin+clavulanic acid 1200 mg or Cefuroksim 1500mg

Group A: antibiotic prophylaxis within 24 hours from the moment of skin incision according to local clinical practice;

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* histologically confirmed diagnosis of very high risk non muscle-invasive bladder carcinoma (cT1NoMo) or muscle-invasive bladder carcinoma (cT2-T4NxM0) with or without neoadjuvant therapy (chemotherapy or immunotherapy are both possible);
* patient should be eligible for radical cystectomy (RC) + pelvic lymph node dissection (PLND), and agreement to undergo curative intent standard RC + PLND (including prostatectomy or hysterectomy if applicable) according to surgeon opinion;
* pelvic lymph node dissection is engaged in two possible variants: extended level to intersection of ureter and iliac vessels; superextended level - up to aortic bifurcation;
* urinary diversion is engaged in two possible variants: orthotopic diversion (J- or U-pouch reservoirs), heterotopic diversion in the Mainz-I modification, Bricker;
* male or female is at least 18 years old at the time of signing the informed consent form;
* female patient is eligible to participate if she is not pregnant, not breastfeeding;
* ECOG performance status of 0 or 1;
* adequate organ function (in accordance with laboratory standards);
* used valid protocol for Enhanced Recovery After Surgery (ERAS protocol) at Hospital (oncourological department);

Exclusion Criteria

* known additional non-urothelial malignancy that is progressing or has required active anticancer treatment ≤3 years of study randomization, with certain exceptions;
* diagnosis of immunodeficiency or receipt of chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior the first dose of study drug;
* replacement doses of corticosteroids are permitted for participants with adrenal insufficiency;
* evidences of uncontrolled diseases (diabetes mellites, noninfectious pneumonitis that required steroids, et.) or any conditions which interfere with the conduct of the research procedures according to doctor opinion;
* presence of 2 or more criteria for systemic inflammatory response syndrome (SIRS) at the time of the patient's admission to the hospital (assessment of these factors 3-7 days before randomization):

* temperature ≥ 38˚С or ≤ 36˚С;
* heart rate (HR) ≥ 90 / min;
* respiratory rate \< 20/min or hyperventilation (Pa CO2 ≤ 32 mm Hg);
* blood leukocytes \>12 ∙ 109 / l or \< 4 ∙ 109 / l, or immature forms \> 10%
* prohibited urinary diversion when planning surgery and signing voluntary consent: diversion into continuous intestine (ureterosigmostomy, Mainz-pouch II operation);
* inadequate organ function:

* Neutrophils \<1.5 x 10 \^ 9 / l
* Platelets \<100 x 10 \^ 9 / l
* ALT\> 3 x VGN
* AST\> 3 x VGN
* Bilirubin\> 1.5 x ULN
* GFR level \<35 ml / min

Minimum Eligible Age

18 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No